

Online supplementary Table S1. Demographic, clinical, laboratory characteristics, and remission achievement at different time frames in 15 patients with GCA treated with TCZ.

Pts	Sex/ Age	GCA diagnosis	FEVER	PMR	Baseline			Mo. 6	Mo.12	Mo.18	Flare	Off-therapy FU (mo.)
					ESR	CRP	VAS	Rem.	Rem.	Rem.		
1	F/81	New	YES		100	5.42	9.0	YES	YES	YES	NO	23
2	F/66	Refract.		YES	43	12.89	10.0	YES	YES	YES	NO	12
3	F/82	New			90	7.03	9.1	YES	YES	YES	NO	11
4	F/78	New	YES	YES	61	1.03	9.2	YES	YES	YES	NO	35
5	F/77	New			46	9.0	9.5	YES	YES	YES	NO	13
6	F/55	New	YES		45	4.5	8.2	YES	YES	YES	NO	29
7	M/80	Refract.			55	2.0	7.8	YES	YES	YES	NO	19
8	F/65	New	YES	YES	76	7.51	9.0	YES	YES	YES	NO	8
9	F/72	New			31	0.01	6.3	YES	YES	YES	NO	8
10	M/75	New		YES	91	5.97	9.0	YES	YES	YES	NO	21
11	M/66	New			45	17.4	8.0	YES	YES	NO*	mo. 14	8
12	F/72	Refract.			55	1.3	8.55	YES	YES	NO	mo. 15	Stable scTCZ/3 wks
13	F/71	New			76	6.47	9.4	YES	YES	NO*	mo. 16	14 mo
14	F/63	Refract.		YES	45	5.05	7.08	YES	YES	NO	mo. 15	Stable scTCZ/3 wks
15	F/57	New			98	9.33	9.0	YES	YES	NO	mo. 13	Stable scTCZ/weekly

**Abbreviations and symbols.** GCA= giant cell arteritis; F= female; M= male; ESR= erythrocyte sedimentation rate; CRP= C-reactive protein; mo= month; Refract.= refractory;

FU= follow-up.

VAS= pain visual analogue scale; mo= month; scTCZ: subcutaneous tocilizumab.

\*Patients 11 and 13 newly achieved the remission after scTCZ restarting and maintained this condition after the interruption over a follow-up of 8 and 14 months.